Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

NCT: NCT03067051 · RECRUITING

NCT IDNCT03067051
StatusRECRUITING
Start Date2017-03-21
Completion2027-12-31

Brief Summary

The rationale for the study is to obtain safety and efficacy data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as photosensitizer for the treatment of recurrent prostate cancer.

Frequently Asked Questions

What is Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System?

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System is a clinical trial registered under NCT03067051. Current status: RECRUITING.

What is the status of NCT03067051?

The current status of NCT03067051 (Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System) is: RECRUITING.

When did Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System start?

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System started on 2017-03-21.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑